Moss, 24 November 2023
 
Reference is made to the annual general meeting 18 May 2022 where guidelines for remuneration of executive personnel were approved. In accordance with these guidelines the board of Gentian Diagnostics ASA has allocated a total of 339,962 options to key employees under the existing option program. 

The following number of options have been allocated to primary insiders of Gentian Diagnostics ASA: 

Hilja Ibert, Chief Executive Officer: 139,962 options. Following the allocations Ms. Ibert holds 6,525 shares and 359,924 options.

Njaal Kind, Group Chief Financial Officer: 40,000 options. Following the allocations Mr. Kind holds 26,125 shares and 180,670 options in the Company.
 
Markus Jaquemar, Chief Commercial Officer: 40,000 options. Following the allocation Mr. Jaquemar holds 87,500 options in the Company.

Aleksandra Havelka, Chief Scientific Officer: 30,000 options. Following the allocation Ms. Havelka hold 2,000 shares and 70,000 options in the Company. 

Torsten Knüttel, Vice President R&D: 30,000 options. Following the allocation Mr. Knüttel holds 1,125 shares and 70,000 options in the Company. 

The exercise price for the options granted is NOK 40,71 being the being the average volume-weighted share price on the Oslo Stock Exchange for the past 10 trading days prior to 24 November 2023. The right to exercise the options is vested over a period of 2 years, with 50% of the options vesting by the end of each year as follows: (i) 50% of the options granted, no earlier than 3 years after the allocation date (ii) 50% of the options granted, no earlier than 4 years after the allocation date. 

Attached are the notifications of the transactions pursuant to the market abuse regulation article 19. 
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

For further information, please contact:
Njaal Kind
CFO, Gentian Diagnostics ASA
E-mail: njaal.kind@gentian.no 
Phone. +47 919 06 525